Follow RSS for latest reports on this topicGilotrif (Afatinib) - Market Research and Reports
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Manufacturer: Boehringer Ingelheim
BioPortfolio's Easy Ordering System
- Search for the report you need from our store
- Make online payment with our easy checkout process
- Receive PDF report via email
Easy Online Payment or Pro Forma Invoice
We accept the following credit cards...
or can supply a pro-forma invoice if required.
We found 1 reports that matched your search.
Refine your search, and find more matches, using the form above.
Global and Chinese Afatinib dimaleate Industry, 2017 Market Research Report
The 'Global and Chinese Afatinib dimaleate Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Afatinib dimaleate industry with a focus on the Chinese market. The report provides key statistics on the market status of the Afatinib dimaleate manufacturers and is a valuable source of guidance and direction for companies and individuals ...Read More >>>
Published by: Prof Research
Prices Starting From: